Promising colon cancer drugs close to FDA approval

12/4/2003 | Forbes

After successful clinical trials last spring, two new colon cancer drugs are expected to receive FDA approval next year. Imclone Systems' and Bristol-Myers Squibb's Erbitux will be used in patients who already have failed other drug regimens, and Genentech's Avastin will be prescribed for first-line use in patients initially diagnosed with advanced color cancer.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ